UB Paderborn / Katalog / Suche / in CDI

The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

European journal of haematology, 2021-03, Vol.106 (3), p.371-379

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of risk features for complication in Gaucher's disease patients: a machine learning analysis of the Spanish registry of Gaucher disease

Orphanet journal of rare diseases, 2020-09, Vol.15 (1), p.256-256, Article 256

2020

Link zum Volltext

Verfügbarkeit prüfen

Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital

Blood coagulation & fibrinolysis, 2013-03, Vol.24 (2), p.194-198

2013

Link zum Volltext

Verfügbarkeit prüfen

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With (90)Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Clinical lymphoma, myeloma and leukemia, 2015-08, Vol.15 (8), p.464

2015

Link zum Volltext

Verfügbarkeit prüfen

Analysis of genotype-phenotype correlation in Gaucher disease type 1 using machine learning techniques

Molecular genetics and metabolism, 2024-02, Vol.141 (2), p.107845, Article 107845

2024

Link zum Volltext

Verfügbarkeit prüfen

Femur Infiltration: A Feature That Predict Bone Complications in Gaucher Disease. Re-Assessing Bone Marrow Involvement through Machine Learning

Blood, 2022-11, Vol.140 (Supplement 1), p.2605-2606

2022

Link zum Volltext

Verfügbarkeit prüfen

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Blood, 2019-11, Vol.134 (Supplement_1), p.2323-2323

2019

Link zum Volltext

Verfügbarkeit prüfen

Social distancing, home-infusion and oral therapy: Evolving paradigms on Gaucher disease management in Spain during COVID-19 pandemic

Molecular genetics and metabolism, 2021-02, Vol.132 (2), p.S15-S15

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Blood, 2020-11, Vol.136 (Supplement 1), p.13-14

2020

Link zum Volltext

Verfügbarkeit prüfen

Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes

Blood, 2021-11, Vol.138 (Supplement 1), p.2599-2599

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of immunoparesis on Gaucher disease (GD): Results from a network relationship analysis of data at diagnosis of the patients included in the Spanish registry of GD

Molecular genetics and metabolism, 2020-02, Vol.129 (2), p.S21-S22

2020

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Blood, 2019-11, Vol.134 (Supplement_1), p.492-492

2019

Link zum Volltext

Verfügbarkeit prüfen

Multiple myeloma and Gaucher disease share features of a cytokine profile

Molecular genetics and metabolism, 2015-02, Vol.114 (2), p.S13-S14

2015

Link zum Volltext

Verfügbarkeit prüfen

Twenty-Five Years Diagnosing Gaucher's Disease in Spain, What We Have Learned?

Blood, 2018-11, Vol.132 (Supplement 1), p.1110-1110

2018

Link zum Volltext

Verfügbarkeit prüfen

Follow-up of bone disease in a large cohort of Gaucher disease

Molecular genetics and metabolism, 2016-02, Vol.117 (2), p.S20-S20

2016

Link zum Volltext

Verfügbarkeit prüfen

Assessing underlying chronic inflammation status in type 1 Gaucher disease patients (GD1): involvement of lipocaline (LCN2) and other monocyte cytokines

Molecular genetics and metabolism, 2017-01, Vol.120 (1-2), p.S22

2017

Link zum Volltext

Verfügbarkeit prüfen

Twenty-five years diagnosing Gaucher disease in Spain: What we have learned?

Molecular genetics and metabolism, 2019-02, Vol.126 (2), p.S22-S22

2019

Link zum Volltext

Verfügbarkeit prüfen

TRAZELGA: Preliminary results of the Spanish prospective, multi-center follow-up study and immune activation markers in adult Gaucher disease patients treated with eliglustat

Molecular genetics and metabolism, 2020-02, Vol.129 (2), p.S21-S21

2020

Link zum Volltext

Verfügbarkeit prüfen

Prospective multi-center national study to standardize the follow-up of type 1 Gaucher disease patients treated with eliglustat under standard of care practice: TRAZELGA project

Molecular genetics and metabolism, 2019-02, Vol.126 (2), p.S22-S23

2019

Link zum Volltext

Verfügbarkeit prüfen

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Clinical lymphoma, myeloma and leukemia, 2015-08, Vol.15 (8), p.464-471

2015

Link zum Volltext

Verfügbarkeit prüfen

Gaucher disease type 3 in Spain. Outcomes and characterization

Molecular genetics and metabolism, 2016-02, Vol.117 (2), p.S20-S20

2016

Link zum Volltext

Verfügbarkeit prüfen

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With90 Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Clinical lymphoma, myeloma and leukemia, 2015, Vol.15 (8), p.464-471

2015

Link zum Volltext

Verfügbarkeit prüfen

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

British journal of haematology, 2019-05, Vol.185 (3), p.480-491

2019

Link zum Volltext

Verfügbarkeit prüfen

Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

British journal of haematology, 2021-03, Vol.192 (6), p.988-996

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

Identification of risk features for complication in Gaucher's disease patients: a machine learning analysis of the Spanish registry of Gaucher disease

Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With (90)Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Analysis of genotype-phenotype correlation in Gaucher disease type 1 using machine learning techniques

Femur Infiltration: A Feature That Predict Bone Complications in Gaucher Disease. Re-Assessing Bone Marrow Involvement through Machine Learning

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Social distancing, home-infusion and oral therapy: Evolving paradigms on Gaucher disease management in Spain during COVID-19 pandemic

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes

Impact of immunoparesis on Gaucher disease (GD): Results from a network relationship analysis of data at diagnosis of the patients included in the Spanish registry of GD

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Multiple myeloma and Gaucher disease share features of a cytokine profile

Twenty-Five Years Diagnosing Gaucher's Disease in Spain, What We Have Learned?

Follow-up of bone disease in a large cohort of Gaucher disease

Assessing underlying chronic inflammation status in type 1 Gaucher disease patients (GD1): involvement of lipocaline (LCN2) and other monocyte cytokines

Twenty-five years diagnosing Gaucher disease in Spain: What we have learned?

Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project

TRAZELGA: Preliminary results of the Spanish prospective, multi-center follow-up study and immune activation markers in adult Gaucher disease patients treated with eliglustat

Prospective multi-center national study to standardize the follow-up of type 1 Gaucher disease patients treated with eliglustat under standard of care practice: TRAZELGA project

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Gaucher disease type 3 in Spain. Outcomes and characterization

Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With90 Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

Suchergebnisse filtern